Diaceutics（DIUX.F）株式概要Diaceutics PLCは診断薬の商業化企業で、製薬会社やバイオテクノロジー企業にデータ、データ分析、導入サービスを提供している。 詳細DIUX.F ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長5/6過去の実績0/6財務の健全性4/6配当金0/6報酬当社が推定した公正価値より16.7%で取引されている 収益は年間88.17%増加すると予測されています リスク分析株式の流動性は非常に低い すべてのリスクチェックを見るDIUX.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.6759.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m87m2016201920222025202620282031Revenue UK£87.1mEarnings UK£11.1mAdvancedSet Fair ValueView all narrativesDiaceutics PLC 競合他社Lifecore BiomedicalSymbol: NasdaqGS:LFCRMarket cap: US$184.9mAlpha TeknovaSymbol: NasdaqGM:TKNOMarket cap: US$208.6mRapid Micro BiosystemsSymbol: NasdaqCM:RPIDMarket cap: US$101.3mQuanterixSymbol: NasdaqGM:QTRXMarket cap: US$126.7m価格と性能株価の高値、安値、推移の概要Diaceutics過去の株価現在の株価UK£1.6752週高値UK£2.5152週安値UK£1.67ベータ0.941ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-12.32%最新ニュースお知らせ • Jan 28Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026お知らせ • Jan 15Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year. For the year 2026, the company expects to deliver 25% revenue growth.お知らせ • Aug 05Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025お知らせ • Jul 31Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company SecretaryDiaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.お知らせ • May 22Diaceutics PLC, Annual General Meeting, Jun 18, 2025Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdomお知らせ • Apr 29Diaceutics PLC to Report Fiscal Year 2024 Final Results on May 13, 2025Diaceutics PLC announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on May 13, 2025最新情報をもっと見るRecent updatesお知らせ • Jan 28Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026お知らせ • Jan 15Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year. For the year 2026, the company expects to deliver 25% revenue growth.お知らせ • Aug 05Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025お知らせ • Jul 31Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company SecretaryDiaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.お知らせ • May 22Diaceutics PLC, Annual General Meeting, Jun 18, 2025Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdomお知らせ • Apr 29Diaceutics PLC to Report Fiscal Year 2024 Final Results on May 13, 2025Diaceutics PLC announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on May 13, 2025お知らせ • Jan 28Diaceutics PLC Announces Remuneration Committee Chair Changes, Effective 1 May 2025Diaceutics PLC announced that Graham Paterson, Senior Independent Director, will, effective 1 May 2025, step down as Chair of the Remuneration Committee (but will remain a member of the Remuneration Committee) and Cheryl MacDiarmid will become Chair of the Remuneration Committee at that time. Cheryl MacDiarmid joined the Company Board as a Non-Executive Director in October 2024 and is a Non-Executive Director and serves as Remuneration Committee Chair at Allergy Therapeutics PLC.お知らせ • Oct 15Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People OfficerDiaceutics PLC announced the appointment of Sandra Blake as Chief People Officer. Sandra has over 25 years leadership experience across Human Resources, Marketing & Innovation in the Technology, Engineering, Banking, Insurance, FMCG, Retail and Energy sectors. Sandra has worked with companies including NatWest Group PLC, Tesco PLC, Cadbury PLC and Kraft Foods Inc.お知らせ • Oct 01Diaceutics plc Announces Board ChangesDiaceutics PLC announces the following changes to its board of directors. Jordan Clark (Chief Data Officer of Diaceutics) will join the Board as an Executive Director effective 1 October 2024. Cheryl MacDiarmid will join the Board as a Non-Executive Director subject to the completion of usual Nominated Adviser due diligence checks and a further announcement will be made in due course. Having been on the Board since March 2019, Mike Wort is stepping down as a Non-Executive Director effective 1 October 2024. Graham Paterson who is currently a Non-Executive Director of Diaceutics will assume the role of Senior Independent Director effective 1 October, 2024. In addition, further to the 23 July 2024 announcement, Diaceutics confirms that Deborah Davis has stepped down from the Board with effect from 1 October 2024 and Peter Keeling has succeeded Deborah as Non-Executive Chair. Cheryl MacDiarmid has over 30 years' experience in the global pharmaceutical sector, notably with GSK, ViiV Healthcare and currently as a Non-Executive Director of AIM-listed Allergy Therapeutics. Cheryl is an internationally recognised opinion leader in the development & commercialisation of medicines. Trained as a pharmacist, she has held numerous senior leadership positions in the UK, EU, US and Canada, with responsibilities including global commercial strategy, P&L, sales, marketing, operations and Board membership. Cheryl is passionate about bringing new therapies to the right patients who can benefit. Jordan Clark is Chief Data Officer at Diaceutics. Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering and data science, to deliver cutting-edge analytics to clients and laboratories. With over a decade of experience at Diaceutics, he has cultivated a profound understanding of the critical role real-world data plays in optimising precision medicine. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise. Additionally, Jordan is renowned for proficiency testing, bioinformatics and biomarker testing, honed through his involvement with UK NEQAS.お知らせ • Sep 09Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024Diaceutics PLC announced that they will report Q2, 2024 results on Sep 17, 2024お知らせ • Aug 27Diaceutics PLC Launches Enhanced Rare-Disease OfferingDiaceutics PLC announced a significant enhancement to its offering which has facilitated a new rare-disease contract win. Access to this new data will revolutionise the early identification of patients, a crucial growth area for pharma companies developing therapies for rare-diseases. Leveraging data utilisation, it will improve earlier patient diagnosis and ultimately, clinical outcomes. Driving this enhancement are 3 key developments within the Diaceutics business as follows: Onboarding of New Data Partners:A number of new rare-disease genomic lab data partners have joined the DXRX network. These partners specialise in genetic testing, including the recognised testing lab in the United States for genetically acquired rare diseases. Advanced Lab Labelling Natural Language Processing (NLP):Diaceutics has updated its advanced lab labelling NLP process to standardise and add value to the new data. This process enables complex labelling such as pathogenic vs Variants of Unknown Significance (VUS) variant calling which until now has proven challenging for the industry to identify. Access to Additional Industry Experts:The company now has a team of industry experts with deep rare-disease experience to support biopharma business opportunities and ensure clients derive maximum value from Diaceutics' deep-data offering. Despite medical and scientific advances, diagnosing rare diseases remains a significant challenge for biopharma companies. Many patients face years of multiple referrals, inconclusive test results and limited treatment benefits. Early diagnosis and quick interventions are crucial for patient survival and quality of life. A precision medicine approach can end these diagnostic odysseys and open opportunities for better clinical outcomes for patients in need. The strategic enhancements announced will enable Diaceutics to identify more patients earlier and in doing so, help pharma customers to better commercialise gene therapies for rare diseases. Leveraging these business enhancements, Diaceutics has already secured a new contract to provide a multi-product solution to support the commercialisation of a therapy in a rare autosomal-recessive disease. This initial contract win demonstrates Diaceutics' ability to meet the complex needs of this market.お知らせ • Aug 19Diaceutics PLC Announces Launch of PMxDiaceutics announced it has launched PMx, a suite of data-driven services built for the promotion and commercialisation of precision medicines and that it has reached agreement with a leading biotech to become its primary promotional partner for the launch of a breakthrough oncology precision medicine in the US using PMx. This partnership represents Diaceutics' seventh enterprise-wide engagement, and the first PMx primary promotional partnership deal whereby Diaceutics' fee structure is aligned with patient recruitment onto therapy. PMx unlocks new revenue streams for Diaceutics and shows the path to considerable increase in revenue per brand. Terms of the Agreement: Under the terms of the agreement, Diaceutics will leverage its DxRx platform, specifically its best-in-class genomic lab data, lab network, omni-channel, digital and peer to peer physician education to enable drug commercialisation. Diaceutics' partner will retain all rights to the license for the drug. This agreement is to deploy PMx through to the end of 2025 and is worth at least £2.4 million in service revenue to Diaceutics, with additional milestone fees estimated to be worth another £1.9 million payable during that period based on successful patient recruitment onto therapy. There is an expectation that the agreement will extend beyond 2025 should the initial phase be successful.お知らせ • Jul 23Diaceutics plc Announces Board ChangesDiaceutics PLC announces the following changes to its board. Deborah Davis has informed the board after three and a half years' service as Non-Executive Chair of Diaceutics, of her intention to step down from the board effective 1 October 2024. Peter Keeling, a co-founder and Executive Director of Diaceutics will succeed Deborah as Non-Executive Chair effective 1 October 2024. Peter will also serve as a Non-Executive Director on the Remuneration and Audit & Risk Committees.お知らせ • Mar 21Diaceutics PLC Launches Significant Upgrade to Its DXRX PlatformDiaceutics PLC has launched a significant upgrade to its DXRX platform, including industry and technologically leading de-identification, generative AI (Diaceutics Large Lab Model, DLLM) and new comprehensive US data sets that include data on social determinants of health. Not only does the upgrade increase the power and efficiency of the platform, but also the applicability of Diaceutics' subscription services into new parts of the precision medicine lifecycle, expanding the Company's addressable market. This new functionality enables the DXRX platform to breakdown siloed datasets and provide greater depth and breadth of Diaceutics' longitudinal insight of the patient journey, at increased speed and scale. As a result of the upgrade, multiple stakeholders within the life sciences industry can now access a best in class, real world data set that is HIPAA compliant, at a pace that previously would not have been possible, helping to address healthcare inequalities and enable more patients to access appropriate therapies.お知らせ • Jan 19+ 1 more updateDiaceutics PLC, Annual General Meeting, Jun 24, 2024Diaceutics PLC, Annual General Meeting, Jun 24, 2024.お知らせ • Sep 27Diaceutics Announces Executive ChangesDiaceutics announced the founder and chief executive of the company is stepping down after nearly two decades at the helm. Peter Keeling co-founded the company in 2005, growing it from a small consulting service provider to a listed company which employs 161 people across Europe and North America. He will step down as chief executive in January, with chief information officer Ryan Keeling becoming chief executive-designate with immediate effect. Ryan, who is Peter’s nephew, joined Diaceutics in 2006 and became a member of the board of directors following the company's listing on the AIM in 2019.お知らせ • Sep 22Diaceutics PLC Announces Executive Changes, Effective 1 October 2023Diaceutics PLC announced the appointment of Graham Paterson as an independent Non-Executive Director of the company effective 1 October 2023. The Company also announced the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023. Graham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc.He has held senior executive roles in a number of companies including TopQ Software Ltd. and SL Capital Partners. Graham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC.お知らせ • Aug 29Diaceutics plc Launches Daily Alerts for Dxrx PlatformDiaceutics PLC announced an important and innovative upgrade to its DXRX platformwhichsees the Company's DXRX Signal productnowproviding alerts on a daily basis. This ground-breaking innovation will provide Diaceutics' customers witheven more timely data to identifypatients who would benefit from their therapies and improve their commercial success. For patients, it means their chances of receiving the optimal therapy within the window of effectiveness is significantly improved. DXRX Signal utilizes real-world data collected from a diverse network of over ~500 labs, encompassing academic, community, and commercial facilities. This comprehensive data pool ensures supply chain reliability and encompasses both geographical and clinical diversity. For Diaceutics' customers, this translates into extensive coverage across a spectrum of medical conditions, including oncology, rare diseases, auto-immune disorders, cardiovascular and infectious diseases. DXRX Signal has identified over 46,000 patients so far in 2023 for its biopharma clients. Building upon the foundation of DXRX Signal, Diaceutics has introduced this pivotal enhancement. These alerts, now available on a daily basis, empower Diaceutics' customers with even timelier insights as they deploy products to pinpoint patients and elevate their commercial success. This innovation equips healthcare professionals with crucial data on a daily basis, and within days of a positive test result. With increased timely access to diagnostic information, physicians can be engaged precisely during the treatment decision window, ensuring the most effective drugs or therapies are offered promptly to patients.お知らせ • Jul 25Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023Diaceutics PLC announced that they will report first half, 2023 results on Sep 26, 2023株主還元DIUX.FUS Life SciencesUS 市場7D0%4.1%1.1%1Yn/a8.3%28.7%株主還元を見る業界別リターン: DIUX.FがUS Life Sciences業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: DIUX.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is DIUX.F's price volatile compared to industry and market?DIUX.F volatilityDIUX.F Average Weekly Movementn/aLife Sciences Industry Average Movement8.0%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: DIUX.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のDIUX.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005213Ryan Keelingwww.diaceutics.com診断薬商業化企業のDiaceutics PLCは、製薬・バイオテクノロジー企業向けにデータ、データ分析、導入サービスを提供している。同社は、精密医療のための診断薬商業化プラットフォームであるDXRXを提供しており、検査機関ネットワークからの診断検査データの複数のパイプラインを統合している。また、DXRXデータソリューションも提供している。DXRXデータソリューションには、治療方針を決定するための検査行動に関する実用的なアラートを提供するDXRXシグナル、患者レベルのデータを使用して医師の検査行動を調査し、検査率、検査方法、医師と検査室の関係を特定するDXRX Physician Mapping、特定の疾患またはバイオマーカーと診断された患者を現在検査している検査室に関する洞察を提供するDXRX Lab Mapping、バイオマーカー検査率レポートを提供するDXRX Disease Testing Rate Trackerなどがある。さらに、マーケット・ランドスケープ、導入、コンサルティング・サービスなどのプロフェッショナル・サービスも提供している。北米、英国、欧州、アジア、および海外で事業を展開している。2005年に法人化され、英国のベルファストに本社を置いている。もっと見るDiaceutics PLC 基礎のまとめDiaceutics の収益と売上を時価総額と比較するとどうか。DIUX.F 基礎統計学時価総額US$189.98m収益（TTM）-US$2.05m売上高(TTM)US$46.51m4.1xP/Sレシオ-92.5xPER（株価収益率DIUX.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計DIUX.F 損益計算書（TTM）収益UK£34.40m売上原価UK£4.78m売上総利益UK£29.63mその他の費用UK£31.15m収益-UK£1.52m直近の収益報告Jun 30, 2025次回決算日May 27, 2026一株当たり利益（EPS）-0.018グロス・マージン86.12%純利益率-4.42%有利子負債／自己資本比率0%DIUX.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/14 11:13終値2026/01/15 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Diaceutics PLC 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Hayley PalmerCanaccord GenuityJulie SimmondsPanmure LiberumJulie SimmondsPanmure Liberum2 その他のアナリストを表示
お知らせ • Jan 28Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026
お知らせ • Jan 15Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year. For the year 2026, the company expects to deliver 25% revenue growth.
お知らせ • Aug 05Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025
お知らせ • Jul 31Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company SecretaryDiaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.
お知らせ • May 22Diaceutics PLC, Annual General Meeting, Jun 18, 2025Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdom
お知らせ • Apr 29Diaceutics PLC to Report Fiscal Year 2024 Final Results on May 13, 2025Diaceutics PLC announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on May 13, 2025
お知らせ • Jan 28Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026
お知らせ • Jan 15Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year. For the year 2026, the company expects to deliver 25% revenue growth.
お知らせ • Aug 05Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025
お知らせ • Jul 31Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company SecretaryDiaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.
お知らせ • May 22Diaceutics PLC, Annual General Meeting, Jun 18, 2025Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdom
お知らせ • Apr 29Diaceutics PLC to Report Fiscal Year 2024 Final Results on May 13, 2025Diaceutics PLC announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on May 13, 2025
お知らせ • Jan 28Diaceutics PLC Announces Remuneration Committee Chair Changes, Effective 1 May 2025Diaceutics PLC announced that Graham Paterson, Senior Independent Director, will, effective 1 May 2025, step down as Chair of the Remuneration Committee (but will remain a member of the Remuneration Committee) and Cheryl MacDiarmid will become Chair of the Remuneration Committee at that time. Cheryl MacDiarmid joined the Company Board as a Non-Executive Director in October 2024 and is a Non-Executive Director and serves as Remuneration Committee Chair at Allergy Therapeutics PLC.
お知らせ • Oct 15Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People OfficerDiaceutics PLC announced the appointment of Sandra Blake as Chief People Officer. Sandra has over 25 years leadership experience across Human Resources, Marketing & Innovation in the Technology, Engineering, Banking, Insurance, FMCG, Retail and Energy sectors. Sandra has worked with companies including NatWest Group PLC, Tesco PLC, Cadbury PLC and Kraft Foods Inc.
お知らせ • Oct 01Diaceutics plc Announces Board ChangesDiaceutics PLC announces the following changes to its board of directors. Jordan Clark (Chief Data Officer of Diaceutics) will join the Board as an Executive Director effective 1 October 2024. Cheryl MacDiarmid will join the Board as a Non-Executive Director subject to the completion of usual Nominated Adviser due diligence checks and a further announcement will be made in due course. Having been on the Board since March 2019, Mike Wort is stepping down as a Non-Executive Director effective 1 October 2024. Graham Paterson who is currently a Non-Executive Director of Diaceutics will assume the role of Senior Independent Director effective 1 October, 2024. In addition, further to the 23 July 2024 announcement, Diaceutics confirms that Deborah Davis has stepped down from the Board with effect from 1 October 2024 and Peter Keeling has succeeded Deborah as Non-Executive Chair. Cheryl MacDiarmid has over 30 years' experience in the global pharmaceutical sector, notably with GSK, ViiV Healthcare and currently as a Non-Executive Director of AIM-listed Allergy Therapeutics. Cheryl is an internationally recognised opinion leader in the development & commercialisation of medicines. Trained as a pharmacist, she has held numerous senior leadership positions in the UK, EU, US and Canada, with responsibilities including global commercial strategy, P&L, sales, marketing, operations and Board membership. Cheryl is passionate about bringing new therapies to the right patients who can benefit. Jordan Clark is Chief Data Officer at Diaceutics. Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering and data science, to deliver cutting-edge analytics to clients and laboratories. With over a decade of experience at Diaceutics, he has cultivated a profound understanding of the critical role real-world data plays in optimising precision medicine. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise. Additionally, Jordan is renowned for proficiency testing, bioinformatics and biomarker testing, honed through his involvement with UK NEQAS.
お知らせ • Sep 09Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024Diaceutics PLC announced that they will report Q2, 2024 results on Sep 17, 2024
お知らせ • Aug 27Diaceutics PLC Launches Enhanced Rare-Disease OfferingDiaceutics PLC announced a significant enhancement to its offering which has facilitated a new rare-disease contract win. Access to this new data will revolutionise the early identification of patients, a crucial growth area for pharma companies developing therapies for rare-diseases. Leveraging data utilisation, it will improve earlier patient diagnosis and ultimately, clinical outcomes. Driving this enhancement are 3 key developments within the Diaceutics business as follows: Onboarding of New Data Partners:A number of new rare-disease genomic lab data partners have joined the DXRX network. These partners specialise in genetic testing, including the recognised testing lab in the United States for genetically acquired rare diseases. Advanced Lab Labelling Natural Language Processing (NLP):Diaceutics has updated its advanced lab labelling NLP process to standardise and add value to the new data. This process enables complex labelling such as pathogenic vs Variants of Unknown Significance (VUS) variant calling which until now has proven challenging for the industry to identify. Access to Additional Industry Experts:The company now has a team of industry experts with deep rare-disease experience to support biopharma business opportunities and ensure clients derive maximum value from Diaceutics' deep-data offering. Despite medical and scientific advances, diagnosing rare diseases remains a significant challenge for biopharma companies. Many patients face years of multiple referrals, inconclusive test results and limited treatment benefits. Early diagnosis and quick interventions are crucial for patient survival and quality of life. A precision medicine approach can end these diagnostic odysseys and open opportunities for better clinical outcomes for patients in need. The strategic enhancements announced will enable Diaceutics to identify more patients earlier and in doing so, help pharma customers to better commercialise gene therapies for rare diseases. Leveraging these business enhancements, Diaceutics has already secured a new contract to provide a multi-product solution to support the commercialisation of a therapy in a rare autosomal-recessive disease. This initial contract win demonstrates Diaceutics' ability to meet the complex needs of this market.
お知らせ • Aug 19Diaceutics PLC Announces Launch of PMxDiaceutics announced it has launched PMx, a suite of data-driven services built for the promotion and commercialisation of precision medicines and that it has reached agreement with a leading biotech to become its primary promotional partner for the launch of a breakthrough oncology precision medicine in the US using PMx. This partnership represents Diaceutics' seventh enterprise-wide engagement, and the first PMx primary promotional partnership deal whereby Diaceutics' fee structure is aligned with patient recruitment onto therapy. PMx unlocks new revenue streams for Diaceutics and shows the path to considerable increase in revenue per brand. Terms of the Agreement: Under the terms of the agreement, Diaceutics will leverage its DxRx platform, specifically its best-in-class genomic lab data, lab network, omni-channel, digital and peer to peer physician education to enable drug commercialisation. Diaceutics' partner will retain all rights to the license for the drug. This agreement is to deploy PMx through to the end of 2025 and is worth at least £2.4 million in service revenue to Diaceutics, with additional milestone fees estimated to be worth another £1.9 million payable during that period based on successful patient recruitment onto therapy. There is an expectation that the agreement will extend beyond 2025 should the initial phase be successful.
お知らせ • Jul 23Diaceutics plc Announces Board ChangesDiaceutics PLC announces the following changes to its board. Deborah Davis has informed the board after three and a half years' service as Non-Executive Chair of Diaceutics, of her intention to step down from the board effective 1 October 2024. Peter Keeling, a co-founder and Executive Director of Diaceutics will succeed Deborah as Non-Executive Chair effective 1 October 2024. Peter will also serve as a Non-Executive Director on the Remuneration and Audit & Risk Committees.
お知らせ • Mar 21Diaceutics PLC Launches Significant Upgrade to Its DXRX PlatformDiaceutics PLC has launched a significant upgrade to its DXRX platform, including industry and technologically leading de-identification, generative AI (Diaceutics Large Lab Model, DLLM) and new comprehensive US data sets that include data on social determinants of health. Not only does the upgrade increase the power and efficiency of the platform, but also the applicability of Diaceutics' subscription services into new parts of the precision medicine lifecycle, expanding the Company's addressable market. This new functionality enables the DXRX platform to breakdown siloed datasets and provide greater depth and breadth of Diaceutics' longitudinal insight of the patient journey, at increased speed and scale. As a result of the upgrade, multiple stakeholders within the life sciences industry can now access a best in class, real world data set that is HIPAA compliant, at a pace that previously would not have been possible, helping to address healthcare inequalities and enable more patients to access appropriate therapies.
お知らせ • Jan 19+ 1 more updateDiaceutics PLC, Annual General Meeting, Jun 24, 2024Diaceutics PLC, Annual General Meeting, Jun 24, 2024.
お知らせ • Sep 27Diaceutics Announces Executive ChangesDiaceutics announced the founder and chief executive of the company is stepping down after nearly two decades at the helm. Peter Keeling co-founded the company in 2005, growing it from a small consulting service provider to a listed company which employs 161 people across Europe and North America. He will step down as chief executive in January, with chief information officer Ryan Keeling becoming chief executive-designate with immediate effect. Ryan, who is Peter’s nephew, joined Diaceutics in 2006 and became a member of the board of directors following the company's listing on the AIM in 2019.
お知らせ • Sep 22Diaceutics PLC Announces Executive Changes, Effective 1 October 2023Diaceutics PLC announced the appointment of Graham Paterson as an independent Non-Executive Director of the company effective 1 October 2023. The Company also announced the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023. Graham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc.He has held senior executive roles in a number of companies including TopQ Software Ltd. and SL Capital Partners. Graham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC.
お知らせ • Aug 29Diaceutics plc Launches Daily Alerts for Dxrx PlatformDiaceutics PLC announced an important and innovative upgrade to its DXRX platformwhichsees the Company's DXRX Signal productnowproviding alerts on a daily basis. This ground-breaking innovation will provide Diaceutics' customers witheven more timely data to identifypatients who would benefit from their therapies and improve their commercial success. For patients, it means their chances of receiving the optimal therapy within the window of effectiveness is significantly improved. DXRX Signal utilizes real-world data collected from a diverse network of over ~500 labs, encompassing academic, community, and commercial facilities. This comprehensive data pool ensures supply chain reliability and encompasses both geographical and clinical diversity. For Diaceutics' customers, this translates into extensive coverage across a spectrum of medical conditions, including oncology, rare diseases, auto-immune disorders, cardiovascular and infectious diseases. DXRX Signal has identified over 46,000 patients so far in 2023 for its biopharma clients. Building upon the foundation of DXRX Signal, Diaceutics has introduced this pivotal enhancement. These alerts, now available on a daily basis, empower Diaceutics' customers with even timelier insights as they deploy products to pinpoint patients and elevate their commercial success. This innovation equips healthcare professionals with crucial data on a daily basis, and within days of a positive test result. With increased timely access to diagnostic information, physicians can be engaged precisely during the treatment decision window, ensuring the most effective drugs or therapies are offered promptly to patients.
お知らせ • Jul 25Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023Diaceutics PLC announced that they will report first half, 2023 results on Sep 26, 2023
